William Richard White - 12 Mar 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Financial Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
12 Mar 2025
Net transactions value
-$30,339
Form type
4
Filing time
14 Mar 2025, 20:24:56 UTC
Previous filing
18 Dec 2024
Next filing
06 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale $30,339 -676 -1.1% $44.88 61,959 12 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.